In 2024 consensus-based guidance was formulated by representatives from the American Society of Anesthesiologists (ASA), the American Gastrointestinal Association (AGA), the American Society for Metabolic and Bariatric Surgery (ASMBS), the International Society of Perioperative Care of Patients with Obesity (ISPCOP), and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) [19], according to which, use of GLP-1RAs and the management in the perioperative period should be based on shared decision-making of the patient, the anaesthetist, the prescribing care team, and the surgeon [19, 20]
Trusted providers like Dr
Nature 632 , 585593 (2024)
Phase 2: weeks 5 through 12 (building momentum) By week five, most people have adapted to the initial dose and gastrointestinal side effects have diminished significantly
Administration of nicotinamide mononucleotide improves oocyte quality of obese mice
Fiber supplements improve digestive regularity